Evaluation of cisplatin in combination with β-elemene as a regimen for prostate cancer chemotherapy

Basic and Clinical Pharmacology and Toxicology

Volumn 107, Issue 5, 2010, Pages 868-876

  Li, Qingdi Quentin ^a,b   Wang, Gangduo ^a   Reed, Eddie ^a   Huang, Lan ^c   Cuff, Christopher F ^a  

^a WEST VIRGINIA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^c HYWE Pharmaceutical Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ELEMENE; CASPASE 10; CASPASE 3; CASPASE 7; CASPASE 9; CISPLATIN; CYTOCHROME C; PROTEIN BCL 2; PROTEIN BCL XL;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER ADJUVANT THERAPY; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CHEMOSENSITIVITY; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG SCREENING; ENZYME ACTIVATION; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROSTATE CARCINOMA; PROTEIN EXPRESSION; PROTEIN SECRETION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; BLOTTING, WESTERN; CASPASES; CELL CULTURE TECHNIQUES; CELL LINE, TUMOR; CELL PROLIFERATION; CISPLATIN; DRUG SYNERGISM; ENZYME-LINKED IMMUNOSORBENT ASSAY; FLOW CYTOMETRY; HUMANS; IN SITU NICK-END LABELING; MALE; PROSTATIC NEOPLASMS; SESQUITERPENES;

EID: 78649537934     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/j.1742-7843.2010.00592.x     Document Type: Article

References (57)

1. Miyamoto H, Messing EM, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate 2004;61:332-53.
2. Joshua AM, Evans A, Van Der Kwast T, Zielenska M, Meeker AK, Chinnaiyan A, Squire JA. Prostatic preneoplasia and beyond. Biochim Biophys Acta 2008;1785:156-81.
3. Gioeli D. Signal transduction in prostrate cancer progression. Clin Sci (Lond) 2005;108:293-308.
4. Diaz M, Patterson SG. Management of androgen-independent prostate cancer. Cancer Control 2004;11:364-73.
5. Ramsay AK, Leung HY. Signalling pathways in prostate carcinogenesis: potentials for molecular-targeted therapy. Clin Sci (Lond) 2009;117:209-28.
6. Gulley J, Dahut WL. Chemotherapy for prostate cancer: finally an advance! Am J Ther 2004;11:288-94.
7. Assikis VJ, Simons JW. Novel therapeutic strategies for androgen-independent prostate cancer: an update. Semin Oncol 2004;31:26-32.
8. Gulley J, Dahut W. Novel clinical trials in androgen-independent prostate cancer. Clin Prostate Cancer 2002;1:51-7.
9. Haas NB. Can chemotherapy alter the course of prostate cancer? Semin Urol Oncol 2001;19:212-21.
10. Fuse H, Muraishi Y, Fujishiro Y, Katayama T. Etoposide, epirubicin and carboplatin in hormone-refractory prostate cancer. Int Urol Nephrol 1996;28:79-85.
11. Sherman SE, Lippard SJ. Structural aspects of platinum anticancer drug interactions wit DNA. Chem Rev 1987;87:1154-81.
12. Shah N, Dizon DS. New-generation platinum agents for solid tumors. Future Oncol 2009;5:33-42.
13. Wang G, Reed E, Li QQ. Molecular basis of cellular response to cisplatin chemotherapy in non-small cell lung cancer. Oncol Rep 2004;12:955-65.
14. Choy H, Park C, Yao M. Current status and future prospects for satraplatin, an oral platinum analogue. Clin Cancer Res 2008;14:1633-8.
15. Oh WK, Tay MH, Huang J. Is there a role for platinum chemotherapy in the treatment of patients with hormone-refractory prostate cancer? Cancer 2007;109:477-86.
16. Drelichman A, Oldford J, Al-Sarraf M. Evaluation of cyclophosphamide, adriamycin, and cis-platinum (CAP) in patients with disseminated prostatic carcinoma. A phase II study. Am J Clin Oncol 1985;8:255-9.
17. Qazi R, Khandekar J. Phase II study of cisplatin for metastatic prostatic carcinoma. An Eastern Cooperative Oncology Group study. Am J Clin Oncol 1983;6:203-5.
18. Merrin C. Treatment of advanced bladder cancer with cis-diamminedichloroplatinum (II NSC 119875): a pilot study. J Urol 1998;119:493-5.
19. Oh WK, Kantoff PW. Docetaxel (Taxotere)-based chemotherapy for hormone-refractory and locally advanced prostate cancer. Semin Oncol 1999;26(Suppl 17):49-54.
20. Huan SD, Stewart DJ, Aitken SE, Segal R, Yau JC. Combination of epirubicin and cisplatin in hormone-refractory metastatic prostate cancer. Am J Clin Oncol 1999;22:471-4.
21. Chang KL, Cheng HL, Huang LW, Hsieh BS, Hu YC, Chih TT, Shyu HW, Su SJ. Combined effects of terazosin and genistein on a metastatic, hormone-independent human prostate cancer cell line. Cancer Lett 2009;276:14-20.
22. Zheng S, Yang H, Zhang S, Wang X, Yu L, Lu J, Li J. Initial study on naturally occurring products from traditional Chinese herbs and vegetables for chemoprevention. J Cell Biochem Suppl 1997;27:106-12.
23. Zhou HY, Shen JK, Hou JS, Qiu YM, Luo QZ. Experimental study on apoptosis induced by elemene in glioma cells (Chinese). Ai Zheng 2003;22:959-63.
24. Li X, Wang G, Zhao J, Ding H, Cunningham C, Chen F, Flynn DC, Reed E, Li QQ. Antiproliferative effect of β-elemene in chemoresistant ovarian carcinoma cells is mediated through arrest of the cell cycle at the G2/M phase. Cell Mol Life Sci 2005;62:894-904.
25. Wang G, Li X, Huang F, Zhao J, Ding H, Cunningham C, Coad JE, Flynn DC, Reed E, Li QQ. Antitumor effect of β-elemene in non-small cell lung cancer cells is mediated via induction of cell cycle arrest and apoptotic cell death. Cell Mol Life Sci 2005;62:881-93.
26. Zhao J, Li QQ, Wang G, Zou B, Li X, Kim JE, Cuff CF, Gardner K. In vitro combination characterization of the new anticancer plant drug β-elemene with taxanes against human lung carcinoma. Int J Oncol 2007;31:241-52.
27. Li QQ, Wang G, Huang L, Cuff CF, Reed E. β-Elemene, a novel plant-derived antineoplastic agent, increases chemosensitivity of lung tumor cells by triggering apoptosis. Oncol Rep 2009;22:161-70.
28. Fisher DE. Apoptosis in cancer therapy: crossing the threshold. Cell 1994;78:539-42.
29. Johnstone RW, Ruefli AA, Lowe SW. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002;108:153-64.
30. Basu A, Castle VP, Bouziane M, Bhalla K, Haldar S. Crosstalk between extrinsic and intrinsic cell death pathways in pancreatic cancer: synergistic action of estrogen metabolite and ligands of death receptor family. Cancer Res 2006;66:4309-18.
31. Zou H, Li Y, Liu X, Wang X. An APAF-1.cytochrome c multimeric complex is a functional apoptosome that activates procaspase-9. J Biol Chem 1999;274:11549-56.
32. Kim SY, Park KW, Kim JY, Shon MY, Yee ST, Kim KH, Rhim JS, Yamada K, Seo KI. Induction of apoptosis by thiosulfinates in primary human prostate cancer cells. Int J Oncol 2008;32:869-75.
33. Ray S, Almasan A. Apoptosis induction in prostate cancer cells and xenografts by combined treatment with Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand and CPT-11. Cancer Res 2003;63:4713-23.
34. Kumi-Diaka J, Sanderson NA, Hall A. The mediating role of caspase-3 protease in the intracellular mechanism of genistein-induced apoptosis in human prostatic carcinoma cell lines, DU145 and LNCaP. Biol Cell 2000;92:595-604.
35. Coffey RN, Watson RW, Hegarty PK, Watson CL, Wolohan L, Brady HR, O'Keane C, Fitzpatrick JM. Priming prostate carcinoma cells for increased apoptosis is associated with up-regulation of the caspases. Cancer 2001;92:2297-308.
36. Tan ML, Ooi JP, Ismail N, Moad AI, Muhammad TS. Programmed cell death pathways and current antitumor targets. Pharm Res 2009;26:1547-60.
37. Hengartner MO. The biochemistry of apoptosis. Nature 2000;407:770-6.
38. Zelivianski S, Spellman M, Kellerman M, Kakitelashvilli V, Zhou XW, Lugo E, Lee MS, Taylor R, Davis TL, Hauke R, Lin MF. ERK inhibitor PD98059 enhances docetaxel-induced apoptosis of androgen-independent human prostate cancer cells. Int J Cancer 2003;107:478-85.
39. Rokhlin OW, Bishop GA, Hostager BS, Waldschmidt TJ, Sidorenko SP, Pavloff N, Kiefer MC, Umansky SR, Glover RA, Cohen MB. Fas-mediated apoptosis in human prostatic carcinoma cell lines. Cancer Res 1997;57:1758-68.
40. Wang G, Reed E, Li QQ. Apoptosis in prostate cancer: progressive and therapeutic implications. Int J Mol Med 2004;14:23-34.
41. Hällström TM, Laiho M. Genetic changes and DNA damage responses in the prostate. Prostate 2008;68:902-18.
42. Nimmanapalli R, Perkins CL, Orlando M, O'Bryan E, Nguyen D, Bhalla KN. Pretreatment with paclitaxel enhances apo-2 ligand/tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis of prostate cancer cells by inducing death receptors 4 and 5 protein levels. Cancer Res 2001;61:759-63.
43. Chakraborty M, Qiu SG, Vasudevan KM, Rangnekar VM. Par-4 drives trafficking and activation of Fas and FasL to induce prostate cancer cell apoptosis and tumor regression. Cancer Res 2001;61:7255-63.
44. So A, Gleave M, Hurtado-Col A, Nelson C. Mechanisms of the development of androgen independence in prostate cancer. World J Urol 2005;23:1-9.
45. Catz SD, Johnson JL. BCL-2 in prostate cancer: a minireview. Apoptosis 2003;8:29-37.
46. Lin Y, Fukuchi J, Hiipakka RA, Kokontis JM, Xiang J. Up-regulation of Bcl-2 is required for the progression of prostate cancer cells from an androgen-dependent to an androgen-independent growth stage. Cell Res 2007;17:531-6.
47. Shi XB, Ma AH, Tepper CG, Xia L, Gregg JP, Gandour-Edwards R, Mack PC, Kung HJ, DeVere White RW. Molecular alterations associated with LNCaP cell progression to androgen independence. Prostate 2004;60:257-71.
48. Zhou JR, Yu L, Zerbini LF, Libermann TA, Blackburn GL. Progression to androgen-independent LNCaP human prostate tumors: cellular and molecular alterations. Int J Cancer 2004;110:800-6.
49. Ohigashi T, Ueno M, Nonaka S, Deguchi N, Murai M. Bcl-2 and androgen receptor gene expression in androgen-independent subclone derived from mouse androgen-dependent cells. Cancer Invest 2002;20:730-6.
50. Miyake H, Monia BP, Gleave ME. Inhibition of progression to androgen-independence by combined adjuvant treatment with antisense BCL-XL and antisense Bcl-2 oligonucleotides plus taxol after castration in the Shionogi tumor model. Int J Cancer 2000;86:855-62.
51. Frenzel A, Grespi F, Chmelewskij W, Villunger A. Bcl2 family proteins in carcinogenesis and the treatment of cancer. Apoptosis 2009;14:584-96.
52. Huerta-Yepez S, Vega M, Jazirehi A, Garban H, Hongo F, Cheng G, Bonavida B. Nitric oxide sensitizes prostate carcinoma cell lines to TRAIL-mediated apoptosis via inactivation of NF-κB and inhibition of Bcl-xl expression. Oncogene 2004;23:4993-5003.
53. Huang YT, Huang DM, Guh JH, Chen IL, Tzeng CC, Teng CM. CIL-102 interacts with microtubule polymerization and causes mitotic arrest following apoptosis in the human prostate cancer PC-3 cell line. J Biol Chem 2005;280:2771-9.
54. Raffo A, Lai JC, Stein CA, Miller P, Scaringe S, Khvorova A, Benimetskaya L. Antisense RNA down-regulation of bcl-2 expression in DU145 prostate cancer cells does not diminish the cytostatic effects of G3139 (Oblimersen). Clin Cancer Res 2004;10:3195-206.
55. Marzo I, Naval J. Bcl-2 family members as molecular targets in cancer therapy. Biochem Pharmacol 2008;76:939-46.
56. Kang MH, Reynolds CP. Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy. Clin Cancer Res 2009;15:1126-32.
57. Kim R. Recent advances in understanding the cell death pathways activated by anticancer therapy. Cancer 2005;103:1551-60.